Predicting the Friction Coefficient of High-Friction Surface Treatment Application Aggregates using the Aggregates\u27 Characteristics

Providing Sufficient Pavement Surface Friction (I.e., Skid Resistance) between Vehicle Tires and Pavement Surface throughout the Pavement Service Life is Considered to Be One of the Main Objectives of Highway Design. Moreover, Vehicle Safety, the Amount of Consumed Fuel, and the Wearing Rate of Vehicle Tires Generally Are Influenced by Pavement Surface Friction. in This Study, a Comprehensive Experimental Testing Program Was Conducted on Different Aggregate Sources, Including Calcined Bauxite and Five Alternative Local Sources, to Assess their Friction Characteristics. the Testing Program Included a British Pendulum Tester (BPT) and a Dynamic Friction Tester (DFT), Which Were Used to Evaluate the Friction Characteristics of the Proposed Aggregates, Along with Basic and Durability Properties Tests. the Aggregate Imaging Measurement System (AIMS) Technique Was Applied to Evaluate the Aggregate Characteristics Due to Micro-Deval Degradation. This Study Provides Two Empirical Models for the Friction Characteristics of High-Friction Surface Treatment (HFST)-Application Aggregates based on the Experimental Results. the First Model Correlates the Friction Coefficient at 20 Km/h (DFC20) with the British Pendulum Number (BPN). the Second Model Expresses DFC20 as a Function of Polishing Resistance of Aggregates, Which is Represented by the Initial and Terminal Aggregate Texture and Angularity Values Measured using the AIMS Device with an overall Coefficient of Determination (R2) of 0.949. the Aggregate Characteristics (I.e., Particle Angularity and Surface Texture) Align Well with the Microtexture Characteristics of the Investigated Sources

Inclusion and neighborhood properties of certain subclasses of p-valent functions of complex order defined by convolution

In this paper we introduce and investigate three new subclasses of $p$-valent analytic functions by using the linear operator $D_{\lambda,p}^m(f*g)(z)$. The various results obtained here for each of these function classes include coefficient bounds, distortion inequalities and associated inclusion relations for $(n,\theta)$-neighborhoods of subclasses of analytic and multivalent functions with negative coefficients, which are defined by means of a non-homogenous differential equation

Differential sandwich theorems for p-valent functions associated with generalized multiplier transformations

In this paper, we obtain some applications of theory of differential subordination, superordination and sandwich results involving an operator

Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies:a report from the EPICOVIDEHA registry

Background: Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/ritonavir treatment in a large cohort of the latter patients. Methods: This is a retrospective cohort study from the multicentre EPICOVIDEHA registry (NCT04733729) on patients with haematological malignancy, who were diagnosed with COVID-19 between January and September 2022. Patients receiving nirmatrelvir/ritonavir were compared to those who did not. A logistic regression was run to determine factors associated with nirmatrelvir/ritonavir administration in our sample. Mortality between treatment groups was assessed with Kaplan–Meier survival plots after matching all the patients with a propensity score. Additionally, a Cox regression was modelled to detect factors associated with mortality in patients receiving nirmatrelvir/ritonavir. Findings: A total of 1859 patients were analysed, 117 (6%) were treated with nirmatrelvir/ritonavir, 1742 (94%) were treated otherwise. Of 117 patients receiving nirmatrelvir/ritonavir, 80% had received ≥1 anti-SARS-CoV-2 vaccine dose before COVID-19 onset, 13% of which received a 2nd vaccine booster. 5% were admitted to ICU. Nirmatrelvir/ritonavir treatment was associated with the presence of extrapulmonary symptoms at COVID-19 onset, for example anosmia, fever, rhinitis, or sinusitis (aOR 2.509, 95%CI 1.448–4.347) and 2nd vaccine booster (aOR 3.624, 95%CI 1.619–8.109). Chronic pulmonary disease (aOR 0.261, 95%CI 0.093–0.732) and obesity (aOR 0.105, 95%CI 0.014–0.776) were not associated with nirmatrelvir/ritonavir use. After propensity score matching, day-30 mortality rate in patients treated with nirmatrelvir/ritonavir was 2%, significantly lower than in patients with SARS-CoV-2 directed treatment other than nirmatrelvir/ritonavir (11%, p = 0.036). No factor was observed explaining the mortality difference in patients after nirmatrelvir/ritonavir administration. Interpretation: Haematological malignancy patients were more likely to receive nirmatrelvir/ritonavir when reporting extrapulmonary symptoms or 2nd vaccine booster at COVID-19 onset, as opposed to chronic pulmonary disease and obesity. The mortality rate in patients treated with nirmatrelvir/ritonavir was lower than in patients with targeted drugs other than nirmatrelvir/ritonavir. Funding: EPICOVIDEHA has received funds from Optics COMMIT (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223).</p

Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

Background: Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/ritonavir treatment in a large cohort of the latter patients. Methods: This is a retrospective cohort study from the multicentre EPICOVIDEHA registry (NCT04733729) on patients with haematological malignancy, who were diagnosed with COVID-19 between January and September 2022. Patients receiving nirmatrelvir/ritonavir were compared to those who did not. A logistic regression was run to determine factors associated with nirmatrelvir/ritonavir administration in our sample. Mortality between treatment groups was assessed with Kaplan-Meier survival plots after matching all the patients with a propensity score. Additionally, a Cox regression was modelled to detect factors associated with mortality in patients receiving nirmatrelvir/ritonavir. Findings: A total of 1859 patients were analysed, 117 (6%) were treated with nirmatrelvir/ritonavir, 1742 (94%) were treated otherwise. Of 117 patients receiving nirmatrelvir/ritonavir, 80% had received ≥1 anti-SARS-CoV-2 vaccine dose before COVID-19 onset, 13% of which received a 2nd vaccine booster. 5% were admitted to ICU. Nirmatrelvir/ritonavir treatment was associated with the presence of extrapulmonary symptoms at COVID-19 onset, for example anosmia, fever, rhinitis, or sinusitis (aOR 2.509, 95%CI 1.448-4.347) and 2nd vaccine booster (aOR 3.624, 95%CI 1.619-8.109). Chronic pulmonary disease (aOR 0.261, 95%CI 0.093-0.732) and obesity (aOR 0.105, 95%CI 0.014-0.776) were not associated with nirmatrelvir/ritonavir use. After propensity score matching, day-30 mortality rate in patients treated with nirmatrelvir/ritonavir was 2%, significantly lower than in patients with SARS-CoV-2 directed treatment other than nirmatrelvir/ritonavir (11%, p&nbsp;=&nbsp;0.036). No factor was observed explaining the mortality difference in patients after nirmatrelvir/ritonavir administration. Interpretation: Haematological malignancy patients were more likely to receive nirmatrelvir/ritonavir when reporting extrapulmonary symptoms or 2nd vaccine booster at COVID-19 onset, as opposed to chronic pulmonary disease and obesity. The mortality rate in patients treated with nirmatrelvir/ritonavir was lower than in patients with targeted drugs other than nirmatrelvir/ritonavir. Funding: EPICOVIDEHA has received funds from Optics COMMIT (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223)

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Background: Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality. Methods: The survey was supported by the Scientific Working Group Infection in Hematology of the European Hematology Association (EHA). Eligible for the analysis were adult patients with HM and laboratory-confirmed COVID-19 observed between March and December 2020. Results: The study sample includes 3801 cases, represented by lymphoproliferative (mainly non-Hodgkin lymphoma n = 1084, myeloma n = 684 and chronic lymphoid leukemia n = 474) and myeloproliferative malignancies (mainly acute myeloid leukemia n = 497 and myelodysplastic syndromes n = 279). Severe/critical COVID-19 was observed in 63.8% of patients (n = 2425). Overall, 2778 (73.1%) of the patients were hospitalized, 689 (18.1%) of whom were admitted to intensive care units (ICUs). Overall, 1185 patients (31.2%) died. The primary cause of death was COVID-19 in 688 patients (58.1%), HM in 173 patients (14.6%), and a combination of both COVID-19 and progressing HM in 155 patients (13.1%). Highest mortality was observed in acute myeloid leukemia (199/497, 40%) and myelodysplastic syndromes (118/279, 42.3%). The mortality rate significantly decreased between the first COVID-19 wave (March–May 2020) and the second wave (October–December 2020) (581/1427, 40.7% vs. 439/1773, 24.8%, p value < 0.0001). In the multivariable analysis, age, active malignancy, chronic cardiac disease, liver disease, renal impairment, smoking history, and ICU stay correlated with mortality. Acute myeloid leukemia was a higher mortality risk than lymphoproliferative diseases. Conclusions: This survey confirms that COVID-19 patients with HM are at high risk of lethal complications. However, improved COVID-19 prevention has reduced mortality despite an increase in the number of reported cases.EPICOVIDEHA has received funds from Optics COMMITTM (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223)

Age, Successive Waves, Immunization, and Mortality in Elderly COVID-19 Haematological Patients: EPICOVIDEHA Findings

Introduction: elderly patients with haematologic malignancies face the highest risk of severe COVID-19 outcomes. The infection impact in different age groups remains unstudied in detail. Methods: We analysed elderly patients (age groups: 65-70, 71-75, 76-80 and &gt;80 years old) with hematologic malignancies included in the EPICOVIDEHA registry between January 2020 and July 2022. Univariable and multivariable Cox regression models were conducted to identify factors influencing death in COVID-19 patients with haematological malignancy. results: the study included data from 3,603 elderly patients (aged 65 or older) with haematological malignancy, with a majority being male (58.1%) and a significant proportion having comorbidities. The patients were divided into four age groups, and the analysis assessed COVID-19 outcomes, vaccination status, and other variables in relation to age and pandemic waves.tThe 90-day survival rate for patients with COVID-19 was 71.2%, with significant differences between groups. The pandemic waves had varying impacts, with the first wave affecting patients over 80 years old, the second being more severe in 65-70, and the third being the least severe in all age groups. factors contributing to 90-day mortality included age, comorbidities, lymphopenia, active malignancy, acute leukaemia, less than three vaccine doses, severe COVID-19, and using only corticosteroids as treatment. Conclusions: These data underscore the heterogeneity of elderly haematological patients, highlight the different impact of COVID waves and the pivotal importance of vaccination, and may help in planning future healthcare efforts

INCLUSION AND NEIGHBORHOOD PROPERTIES OF A CERTAIN SUBCLASSES OF P-VALENT FUNCTIONS WITH NEGATIVE COEFFICIENTS

By means of Ruscheweyh derivative operator, we introduced and investigated two new subclasses of p-valent analytic functions.The various results obtained here for each of these function class include coefficient bounds and distortion inequalities, associated inclusion relations for the (n, θ)-neighborhoods of subclasses of analytic and multivalent functions with negative coefficients, which are defined by means of non-homogenous differential equation. 1 Introductin Let Tp(n) denote the class of functions of the form: f(z) = z p ∞∑ − akz k k=n+p (ak ≥ 0; p, n ∈ N = {1, 2,....}), (1.1) which are analytic and p-valent in the open unit disc U = {z: |z | &lt; 1}. The modified Hadamard product (or convolution) of the function f(z) given by (1.1) and the function g(z) ∈ Tp(n) given by g(z) = z p ∞∑ − bkz k k=n+p (bk ≥ 0; p, n ∈ N) (1.2) is defined by (f ∗ g)(z) = z p ∞∑ − akbkz k = (g ∗ f)(z). (1.3) k=n+

Inclusion and neighborhood properties of certain subclasses of p-valent functions of complex order defined by convolution

In this paper we introduce and investigate three new subclasses of $p$-valent analytic functions by using the linear operator $D_{\lambda,p}^m(f*g)(z)$. The various results obtained here for each of these function classes include coefficient bounds, distortion inequalities and associated inclusion relations for $(n,\theta)$-neighborhoods of subclasses of analytic and multivalent functions with negative coefficients, which are defined by means of a non-homogenous differential equation